Change in Apo B100/A1 Ratio in Children With Epilepsy on Monotherapy With Sodium Valproate, Oxcarbazepine or Levetiracetam

被引:1
|
作者
Lekhwani, Seema [1 ]
Dhama, Anjali [2 ]
Kaushik, Jaya Shankar [3 ]
机构
[1] Pt BD Sharma Post Grad Inst Med Sci, Dept Biochem, Rohtak, Haryana, India
[2] NC Med Coll, Dept Biochem, Panipat, Haryana, India
[3] All India Inst Med Sci, Dept Pediat, Gauhati, Assam, India
关键词
Adverse effect; Cardiovascular risk; Lipid profile; Outcome; A-I; CHOLESTEROL;
D O I
10.1007/s13312-023-2916-z
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
A prospective longitudinal study was conducted to assess the Apo B100/A1 ratio as a marker of cardiovascular risk in children with epilepsy aged 5-14 years on long-term anti-seizure medication monotherapy with either sodium valproate, oxcarbazepine, or levetiracetam. Apo B100/A1 ratio showed an increase after six months of monotherapy with oxcarbazepine (P=0.05).
引用
收藏
页码:492 / 494
页数:3
相关论文
共 5 条
  • [1] Change in Apo B100/A1 Ratio in Children With Epilepsy on Monotherapy With Sodium Valproate, Oxcarbazepine or Levetiracetam
    Seema Lekhwani
    Anjali Dhama
    Jaya Shankar Kaushik
    Indian Pediatrics, 2023, 60 : 492 - 494
  • [2] Change of serum sodium level after oxcarbazepine monotherapy in children with epilepsy
    Nam, S.
    Lee, Y.
    EPILEPSIA, 2007, 48 : 106 - 106
  • [3] Plasma brain natriuretic peptide levels in children with idiopathic epilepsy treated with long-term sodium valproate and oxcarbazepine monotherapy
    Vartzelis, G.
    Attilakos, A.
    Tsentidis, C.
    Kalimeraki, L.
    Maritsi, D.
    Marmarinos, A.
    Garoufi, A.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2021, 35 (04): : 1293 - 1297
  • [4] 载脂蛋白APO、A1,APO、B100的变化与中医辨证的关系观察
    郭川
    饶吉
    四川中医, 1993, (12) : 18 - 18
  • [5] Efficacy of levetiracetam combined with sodium valproate on pediatric epilepsy and its effect on serum miR-106b in children
    Zhao, Jiaqiang
    Sang, Yan
    Zhang, Yuan
    Zhang, Dongli
    Chen, Jiao
    Liu, Xiaoming
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2019, 18 (06) : 4436 - 4442